Where does David Bonita work?

David Bonita is General Partner at OrbiMed.

What check size does David Bonita write?

David Bonita typically writes checks of $1M – $75M.

What boards does David Bonita sit on?

David Bonita holds tracked board seats at Acutus Medical, Adelabio, Clementia Pharmaceuticals, Ikena Oncology, Inc., Imara, Prelude Therapeutics, SI-BONE, Thrombolex, Treeline Biosciences, Tricida.

Where did David Bonita go to school?

David Bonita studied at Columbia Business School (MBA); Columbia University Vagelos College of Physicians and Surgeons (MD); Harvard University (BA, Biology).

David Bonita

Investor

General Partner at OrbiMed

New York, New York

Writes $1M – $75M checks · typically $4M

Find your path to David

4,512 people in our graph share verified history with David — schools, employers, funds. One of them is your warm intro.

Adam ValkinunlockedDavid: together at Harvard University (1993–1996)

×6David: together at Morgan Stanley

×5David: together at Harvard University

About

David Bonita is a physician-investor (MD, Harvard; clinical work at Mass General) with over two decades investing, rising to General Partner in 2020, and board roles in oncology and therapeutics.

Invests in

AI & Machine LearningBiotechHealthtechMedical Devices

Experience

OrbiMedGeneral Partnercurrent2020 — present
OrbiMedPrivate Equity Partner2013 — 2020
OrbiMedPrivate Equity Principal2007 — 2013
OrbiMedSenior Associate2004 — 2007
Morgan StanleyFinancial Analyst1998 — 1999
UBS Investment BankFinancial Analyst1997 — 1998

Skills & more

Venture CapitalPrivate EquityFinancial Modeling2Due DiligenceValuation

From David's professional profile.

Deals · 10

ThrombolexBoard seat

via OrbiMed · filed Mar 2026 · $51.1M raise

Treeline BiosciencesBoard seat

via OrbiMed · filed Sep 2025 · $250M raise

Ikena Oncology, Inc.Board seat

via OrbiMed · filed Jul 2025 · $75M raise

Acutus MedicalBoard seat

via OrbiMed · filed Jul 2022 · $4.2M raise

ImaraBoard seat

via OrbiMed · filed Mar 2019 · $63M raise

TricidaBoard seat

via OrbiMed · filed Jul 2016 · $55.5M raise

Prelude TherapeuticsBoard seat

via OrbiMed · filed Jul 2016 · $5M raise

SI-BONEBoard seat

via OrbiMed · filed Jun 2016 · $21M raise

ViewrayBoard seat

via OrbiMed · filed Aug 2015

Clementia PharmaceuticalsBoard seat

via OrbiMed · filed Jul 2015 · $60M raise

Attribution from SEC filings, press coverage, and firm rosters.

Other disclosed investments

Board seats

Adelabio

Per SEC Form D filings.

Colleagues at OrbiMed

Aldo Brambilla

Associate at Silver Lake Partners

Alexander M. Cooper

Investor at OrbiMed

Anat Naschitz

Executive Officer at OrbiMed

Anat Nursella

Venture Partner at OrbiMed

Andrew P. Kanarek, CFA, CIPM

Investor at Insight Partners

Network3

Anat Nursella

Venture Partner at OrbiMed

Investors connected to David in public investor directories — a warm-intro map.

Frequently asked questions

Who is David Bonita?: David Bonita is a physician-investor (MD, Harvard; clinical work at Mass General) with over two decades investing, rising to General Partner in 2020, and board roles in oncology and therapeutics.
Where does David Bonita work?: David Bonita is General Partner at OrbiMed.
What does David Bonita invest in?: David Bonita invests in AI & Machine Learning, Biotech, Healthtech, Medical Devices.
What check size does David Bonita write?: David Bonita typically writes checks of $1M – $75M.
What boards does David Bonita sit on?: David Bonita holds tracked board seats at Acutus Medical, Adelabio, Clementia Pharmaceuticals, Ikena Oncology, Inc., Imara, Prelude Therapeutics, SI-BONE, Thrombolex, Treeline Biosciences, Tricida.
Where did David Bonita go to school?: David Bonita studied at Columbia Business School (MBA); Columbia University Vagelos College of Physicians and Surgeons (MD); Harvard University (BA, Biology).

Same school

Also attended Columbia Business School972

Ryan PetersenFounder & CEO of Flexport Aryo TehranianManaging Director at Mayfair Equity Partners Yibo NianInvestment Director at Intel Capital Kesha CashFounder & General Partner at Impact America Fund Mahati SridharPartner, Rise of the Rest at Revolution Giuseppe IademarcoHead of Global Partnership at P101 Ventures

+ 966 more

Also attended Columbia University Vagelos College of Physicians and Surgeons27

Tristan HuntPartner at Averin Capital Deborah PalestrantPartner, Executive Chair, 4:59 Initiative at 5AM Ventures Shreeram AradhyeInvestor at Novartis Venture Fund Joseph MayerPartner at HLM Investment Partners Joan LaRovereOperating Partner at iSelect Fund Curt LaBelleVenture Partner at Adjuvant Capital

+ 21 more

Also attended Harvard University2,000

Ron ConwayFounder of SV Angel Alfred LinPartner at Sequoia Capital Chris DixonFounder & Managing Partner of a16z crypto at Andreessen Horowitz Sarah TavelVenture Partner at Benchmark Danny RimerPartner at Index Ventures Laela SturdyManaging Partner at CapitalG

+ 1,994 more

Shared employers

Also worked at OrbiMed80

Ryan LoggieDirector of Finance and Tax at Casdin Capital Matthew R. PattersonVenture Partner - US Investments at SR One Capital Management Leon ChenPartner at The Column Group Anna BittonCFO at Torch Capital Ken TangPrincipal at K2 HealthVentures Tadd WesselManaging Partner at Scion Life Sciences

+ 74 more

Also worked at Morgan Stanley1,519

Mary MeekerFounder & General Partner at BOND Aileen LeeFounder & Managing Partner of Cowboy Ventures Jenny LeeSenior Managing Partner at Granite Asia Luciana LixandruPartner at Sequoia Capital David VélezFounder & CEO of Nubank James DetweilerVP of Investments at Felicis Ventures

+ 1,513 more

Also worked at UBS Investment Bank1,000

Vlad YatsenkoCo-founder & CTO of Revolut Jen WangDeal Operations Manager at Felicis Ventures Martin MignotInvestor at Index Ventures BirgitteInvestor at Investinor Sauvanne Saint-LégerInvestor at Daphni Elena PantaziPartner & Head of Platform at Northzone

+ 994 more